BRIEF—Sandoz launches Suboxone generic in the USA

Novartis’ US-based generic division Sandoz has launched an authorized generic of Suboxone (buprenorphine/naloxone) in the USA. The therapy is indicated for the treatment of opioid dependence.

According to market analyst IQVIA, US-based sales for Suboxone were around $2 billion in 2018.

President Carol Lynch said: "We are excited to have the opportunity to further increase access to this critical medicine in the US market and to be a part of the solution to a healthcare crisis that the nation is facing.”